Form 4: Doximity Director Kira Scherer Wampler Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Kira Scherer Wampler exercised stock options and sold 2,500 shares of Doximity Class A Common Stock at $27.22 per share under a pre-arranged trading plan.
Summary
- On May 17, 2024, Kira Scherer Wampler, a director of Doximity, Inc., executed a transaction involving the company's stock.
- Wampler exercised a stock option to acquire 2,500 shares of Class A Common Stock at an exercise price of $1.54.
- Simultaneously, Wampler sold 2,500 shares of Class A Common Stock at a price of $27.22 per share.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 24, 2023.
- Following these transactions, Wampler directly owns 10,258 shares of Class A Common Stock and 504,700 shares of Class B Common Stock.
- Wampler also holds options for 2,500 shares of Class B Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock activity.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the trading activities of company directors. It is common for executives to utilize 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their insiders.
- The use of 10b5-1 trading plans is a common strategy among corporate executives to sell shares in a pre-planned manner, mitigating concerns about trading on non-public information.
- Comparable companies such as Teladoc Health, Inc. and GoodRx Holdings, Inc. also have frequent Form 4 filings related to insider transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a director.
- The impact is likely minimal as the sale was conducted under a pre-arranged trading plan.
Key Dates
| Date | Description |
|---|---|
| March 27, 2020 | Start date for the stock option vesting in 36 equal monthly installments. |
| June 10, 2020 | Date the stock option was granted. |
| August 24, 2023 | Date the Reporting Person adopted the Rule 10b5-1 trading plan. |
| May 17, 2024 | Date of the transaction: stock option exercise and sale of shares. |
| June 09, 2030 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.